 CAMBRIDGE, Mass., July 20, 2021 GLOBE NEWSWIRE -- TCR2 Therapeutics Inc. Nasdaq: TCRR, a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients with solid tumors, today announced the appointment of Peter Olagunju as Chief Technical Officer where he will oversee process development, manufacturing, quality control and technical operations for the Companys TRuC-T cell programs and emerging pipeline. 